Results 11 to 20 of about 1,456,631 (242)

Beta-Lactamase Inhibitors

open access: yes, 2022
Archive of beta-lactamase-inhibitors containing sub-folders named after each compound and its net charge. Every compound's folder contains a total of 20 files distributed into three sub-directories reporting QM (QM/), FF (FF/), and MD (MD ...
Khanna NR, Gerriets V.
europepmc   +4 more sources

Production of β-Lactamase Inhibitors by Streptomyces Species

open access: yesAntibiotics, 2018
β-Lactamase inhibitors have emerged as an effective alternative to reduce the effects of resistance against β-lactam antibiotics. The Streptomyces genus is known for being an exceptional natural source of antimicrobials and β-lactamase ...
Daniela de Araújo Viana Marques   +5 more
doaj   +2 more sources

ß-Lactam-ß-lactamase Inhibitor Combination against ESBL-Producing Enterobacteriaceae

open access: yesMajallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd, 2016
In the last decades, Extended-Spectrum-β-Lactamases (ESBLs) in gram negative bacilli have appeared as a significant mechanism of resistance to antibiotics. Although resistance to carbapenems is increasing among bacteria, they are still the treatment
A Hashemi
doaj   +1 more source

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms. [PDF]

open access: yesAntibiotics (Basel), 2022
The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol
Bianco G   +7 more
europepmc   +2 more sources

Docking and Molecular Dynamic of Microalgae Compounds as Potential Inhibitors of Beta-Lactamase [PDF]

open access: yes, 2022
Bacterial resistance is responsible for a wide variety of health problems, both in children and adults. The persistence of symptoms and infections are mainly treated with β-lactam antibiotics.
Yani Aranguren-Díaz   +15 more
core   +1 more source

Rapid Evolution of a Fragment-like Molecule to Pan-Metallo-Beta-Lactamase Inhibitors: Initial Leads toward Clinical Candidates

open access: yes, 2022
With the emergence and rapid spreading of NDM-1 and existence of clinically relevant VIM-1 and IMP-1, discovery of pan inhibitors targeting metallo-beta-lactamases (MBLs) became critical in our battle against bacterial infection.
Winnie Prosise (14231582)   +43 more
core   +2 more sources

Treatment in Infections by Enterobacterales Producing Extended Spectrum Betalactamase. Systematic Review

open access: yesKasmera, 2021
Extended spectrum beta-lactamases producing Enterobacterales have become pandemic worldwide representing a major public health threat due to poor outcomes and high mortality associated with infections by these bacteria, consequently it is essential to ...
Carli Samira Aziz Delgado   +1 more
doaj   +1 more source

Functional Dynamics of Substrate Recognition in TEM Beta-Lactamase

open access: yesEntropy, 2022
The beta-lactamase enzyme provides effective resistance to beta-lactam antibiotics due to substrate recognition controlled by point mutations. Recently, extended-spectrum and inhibitor-resistant mutants have become a global health problem.
Chris Avery   +2 more
doaj   +1 more source

Escape mutations circumvent a tradeoff between resistance to a beta-lactam and resistance to a beta-lactamase inhibitor

open access: yesNature Communications, 2020
Beta-lactam antibiotics and beta-lactamase inhibitors compete for the same binding site on beta-lactamases; thus, mutations that increase beta-lactamase activity likely increase also susceptibility to the inhibitor. Here, Russ et al.
Dor Russ   +8 more
doaj   +1 more source

Neutralizing Carbapenem Resistance by Co-Administering Meropenem with Novel β-Lactam-Metallo-β-Lactamase Inhibitors

open access: yesAntibiotics, 2023
Virulent Enterobacterale strains expressing serine and metallo-β-lactamases (MBL) genes have emerged responsible for conferring resistance to hard-to-treat infectious diseases. One strategy that exists is to develop β-lactamase inhibitors to counter this
Nakita Reddy   +17 more
doaj   +1 more source

Home - About - Disclaimer - Privacy